RT @NatureBiotech: In Brief: FDA rejects Intercept Pharmaceuticals’ obeticholic acid for nonalcoholic steatohepatitis (NASH), another disap…
RT @NatureBiotech: In Brief: FDA rejects Intercept Pharmaceuticals’ obeticholic acid for nonalcoholic steatohepatitis (NASH), another disap…
RT @NatureBiotech: In Brief: FDA rejects Intercept Pharmaceuticals’ obeticholic acid for nonalcoholic steatohepatitis (NASH), another disap…
RT @NatureBiotech: In Brief: FDA rejects Intercept Pharmaceuticals’ obeticholic acid for nonalcoholic steatohepatitis (NASH), another disap…
RT @NatureBiotech: In Brief: FDA rejects Intercept Pharmaceuticals’ obeticholic acid for nonalcoholic steatohepatitis (NASH), another disap…
In Brief: FDA rejects Intercept Pharmaceuticals’ obeticholic acid for nonalcoholic steatohepatitis (NASH), another disappointment for a crowded field littered with failures $ICPT https://t.co/WLK9ieAlgW